Points to remember
- Novocure& Treatment for Ovarian Cancer did not show significant results in a phase 3 trial.
- The study indicated that the treatment did not #39;was only slightly more effective than chemotherapy.
- Novocure shares fell to their lowest level since 2017.
Shares of Novocure (NVCR) plunged 37.5% on Monday after the cancer treatment provider announced that a Phase 3 trial of its Tumor Treatment Fields (TTFields) treatment for patients with cancer #39;ovarian cancer had not reached its goal.
TTFields are electric fields which help prevent cancer cells from dividing, and Novocure's TTFields are currently used to treat brain and lung cancers.
The company said the overall average Survival of patients treated with TTFields and the chemotherapy drug paclitaxel was 12.2 months, compared with 11.9 months for patients who received paclitaxel alone.
Executive Chairman William Doyle said that while the result was disappointing, the company was encouraged by indications of the “potential for clinical benefit when TTFields therapy is initiated early in a patient's treatment journey.” a patient “.
“We are committed to continuing conduct research with TTFields and explore innovative approaches to address this area of immense and unmet need,” 34; said lead researcher Dr Ignace Vergote, who led the trial.
Novocure shares fell at their lowest level since 2017 following the news.
Do you have any news tip for Investopedia reporters? Please email us at firstname.lastname@example.org